Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
Featured trial
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

  • 208 views
  • 08 Nov, 2020
  • 1 location
Effects of Anakinra in Subjects With Autoimmune Inner Ear Disease

A Phase II randomized, placebo controlled study design of anakinra (Kineret) in corticosteroid-resistant Meniere's disease (CR-MD)and corticosteroid-resistant autoimmune inner ear disease (CR

  • 28 views
  • 14 Feb, 2022
  • 1 location
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

cholesterol, have also been shown to decrease inflammation in general as well as at the level of the vessel wall. Anakinra, a therapy that blocks the high levels of interleukin 1 (IL1) that leads to

heart disease
  • 1 views
  • 13 Mar, 2022
  • 1 location
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

This phase II trial studies how well anakinra works in decreasing the occurrence of cytokine release syndrome (CRS) and damage to the nerves (neurotoxicity) in patients with B-cell non-Hodgkin

cell therapy
  • 0 views
  • 09 Apr, 2022
  • 1 location
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

with Schnitzler's syndrome (SchS) currently well controlled by anakinra therapy. At least 5 but no more than 10 subjects will be enrolled.

  • 3 views
  • 05 Mar, 2022
  • 1 location
Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis (MAGiC-ART)

therapeutic agent for cardiac sarcoidosis. In the current study, researchers aim to evaluate the safety and efficacy of IL-1 blockade with anakinra (IL-1 receptor antagonist) in patients with cardiac

  • 45 views
  • 17 Feb, 2022
  • 2 locations
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis (CRI-RA)

(RCTs) have explored the efficacy and safety of combining tumour necrosis factor (TNF) inhibitor with another biologic (anakinra, abatacept, rituximab or bimekizumab). Baricitinib is a selective

tumor necrosis factor
tumour necrosis
anakinra
baricitinib
tofacitinib
  • 0 views
  • 15 Mar, 2022
  • 6 locations
Woodsmoke Particulate + Prednisone (Smokisone)

Deployment of military personnel has been associated with increased respiratory illness likely due, in part, to inhalation of unusual particulate matter (PM), such as from burn pits. Inflammation is a key initial response to inhaled particulates. The researchers have developed a protocol using inhaled wood smoke particles (WSP) as a …

Accepts healthy volunteers
  • 0 views
  • 08 Aug, 2022
  • 1 location
Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.

Colchicine acts upstream in the cytokines cascade by inhibiting the NLRP3 inflammasome while IL-6 receptor antagonists (tocilizumab) block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing …

  • 0 views
  • 10 Dec, 2021
  • 1 location
Randomised Evaluation of COVID-19 Therapy (RECOVERY)

), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Infliximab, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) prevents death in patients with COVID-19

fever
covid-19
azithromycin
cough
shortness of breath
  • 0 views
  • 19 Apr, 2022
  • 6 locations